vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and Donnelley Financial Solutions, Inc. (DFIN). Click either name above to swap in a different company.
Donnelley Financial Solutions, Inc. is the larger business by last-quarter revenue ($172.5M vs $139.2M, roughly 1.2× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 3.6%, a 31.9% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 10.4%). Donnelley Financial Solutions, Inc. produced more free cash flow last quarter ($47.9M vs $34.6M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs -7.9%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Donnelley Financial Solutions (DFIN) is a financial compliance company based in Chicago, Illinois, United States. The company provides software as a service (SaaS) products, software-enabled services (SeS), print, and compliance services related to US Securities and Exchange Commission regulations to companies in capital and investment markets.
ADMA vs DFIN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $172.5M |
| Net Profit | $49.4M | $6.2M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | 8.3% |
| Net Margin | 35.5% | 3.6% |
| Revenue YoY | 18.4% | 10.4% |
| Net Profit YoY | -55.9% | -1.6% |
| EPS (diluted) | $0.20 | $0.31 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $172.5M | ||
| Q3 25 | $134.2M | $175.3M | ||
| Q2 25 | $122.0M | $218.1M | ||
| Q1 25 | $114.8M | $201.1M | ||
| Q4 24 | $117.5M | $156.3M | ||
| Q3 24 | $119.8M | $179.5M | ||
| Q2 24 | $107.2M | $242.7M | ||
| Q1 24 | $81.9M | $203.4M |
| Q4 25 | $49.4M | $6.2M | ||
| Q3 25 | $36.4M | $-40.9M | ||
| Q2 25 | $34.2M | $36.1M | ||
| Q1 25 | $26.9M | $31.0M | ||
| Q4 24 | $111.9M | $6.3M | ||
| Q3 24 | $35.9M | $8.7M | ||
| Q2 24 | $32.1M | $44.1M | ||
| Q1 24 | $17.8M | $33.3M |
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
| Q4 25 | 45.1% | 8.3% | ||
| Q3 25 | 38.0% | 16.1% | ||
| Q2 25 | 35.1% | 24.2% | ||
| Q1 25 | 30.4% | 22.8% | ||
| Q4 24 | 32.6% | 6.0% | ||
| Q3 24 | 33.1% | 10.1% | ||
| Q2 24 | 36.6% | 26.6% | ||
| Q1 24 | 26.7% | 21.9% |
| Q4 25 | 35.5% | 3.6% | ||
| Q3 25 | 27.1% | -23.3% | ||
| Q2 25 | 28.1% | 16.6% | ||
| Q1 25 | 23.4% | 15.4% | ||
| Q4 24 | 95.2% | 4.0% | ||
| Q3 24 | 30.0% | 4.8% | ||
| Q2 24 | 29.9% | 18.2% | ||
| Q1 24 | 21.7% | 16.4% |
| Q4 25 | $0.20 | $0.31 | ||
| Q3 25 | $0.15 | $-1.49 | ||
| Q2 25 | $0.14 | $1.28 | ||
| Q1 25 | $0.11 | $1.05 | ||
| Q4 24 | $0.45 | $0.21 | ||
| Q3 24 | $0.15 | $0.29 | ||
| Q2 24 | $0.13 | $1.47 | ||
| Q1 24 | $0.08 | $1.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $24.5M |
| Total DebtLower is stronger | $72.1M | $171.3M |
| Stockholders' EquityBook value | $477.3M | $379.2M |
| Total Assets | $624.2M | $800.4M |
| Debt / EquityLower = less leverage | 0.15× | 0.45× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $24.5M | ||
| Q3 25 | $61.4M | $22.7M | ||
| Q2 25 | $90.3M | $33.8M | ||
| Q1 25 | $71.6M | $16.2M | ||
| Q4 24 | $103.1M | $57.3M | ||
| Q3 24 | $86.7M | $33.6M | ||
| Q2 24 | $88.2M | $35.0M | ||
| Q1 24 | $45.3M | $43.7M |
| Q4 25 | $72.1M | $171.3M | ||
| Q3 25 | $72.4M | $154.7M | ||
| Q2 25 | — | $190.1M | ||
| Q1 25 | — | $189.5M | ||
| Q4 24 | $72.3M | $124.7M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | $379.2M | ||
| Q3 25 | $431.2M | $423.1M | ||
| Q2 25 | $398.3M | $432.1M | ||
| Q1 25 | $373.4M | $419.9M | ||
| Q4 24 | $349.0M | $436.1M | ||
| Q3 24 | $231.9M | $444.5M | ||
| Q2 24 | $188.3M | $441.5M | ||
| Q1 24 | $153.7M | $408.9M |
| Q4 25 | $624.2M | $800.4M | ||
| Q3 25 | $568.7M | $816.3M | ||
| Q2 25 | $558.4M | $874.7M | ||
| Q1 25 | $510.6M | $852.8M | ||
| Q4 24 | $488.7M | $841.6M | ||
| Q3 24 | $390.6M | $843.6M | ||
| Q2 24 | $376.4M | $882.9M | ||
| Q1 24 | $350.9M | $867.8M |
| Q4 25 | 0.15× | 0.45× | ||
| Q3 25 | 0.17× | 0.37× | ||
| Q2 25 | — | 0.44× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | 0.21× | 0.29× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $59.8M |
| Free Cash FlowOCF − Capex | $34.6M | $47.9M |
| FCF MarginFCF / Revenue | 24.8% | 27.8% |
| Capex IntensityCapex / Revenue | 0.8% | 6.9% |
| Cash ConversionOCF / Net Profit | 0.72× | 9.65× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $107.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $59.8M | ||
| Q3 25 | $13.3M | $74.4M | ||
| Q2 25 | $21.1M | $68.4M | ||
| Q1 25 | $-19.7M | $-37.7M | ||
| Q4 24 | $50.2M | $56.4M | ||
| Q3 24 | $25.0M | $86.4M | ||
| Q2 24 | $45.6M | $56.2M | ||
| Q1 24 | $-2.2M | $-27.9M |
| Q4 25 | $34.6M | $47.9M | ||
| Q3 25 | $-1.1M | $59.2M | ||
| Q2 25 | $18.7M | $51.7M | ||
| Q1 25 | $-24.4M | $-51.0M | ||
| Q4 24 | $47.5M | $41.3M | ||
| Q3 24 | $24.0M | $67.3M | ||
| Q2 24 | $43.6M | $36.8M | ||
| Q1 24 | $-4.6M | $-40.2M |
| Q4 25 | 24.8% | 27.8% | ||
| Q3 25 | -0.8% | 33.8% | ||
| Q2 25 | 15.3% | 23.7% | ||
| Q1 25 | -21.2% | -25.4% | ||
| Q4 24 | 40.4% | 26.4% | ||
| Q3 24 | 20.0% | 37.5% | ||
| Q2 24 | 40.7% | 15.2% | ||
| Q1 24 | -5.6% | -19.8% |
| Q4 25 | 0.8% | 6.9% | ||
| Q3 25 | 10.7% | 8.7% | ||
| Q2 25 | 2.0% | 7.7% | ||
| Q1 25 | 4.1% | 6.6% | ||
| Q4 24 | 2.3% | 9.7% | ||
| Q3 24 | 0.9% | 10.6% | ||
| Q2 24 | 1.9% | 8.0% | ||
| Q1 24 | 2.9% | 6.0% |
| Q4 25 | 0.72× | 9.65× | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | 1.89× | ||
| Q1 25 | -0.73× | -1.22× | ||
| Q4 24 | 0.45× | 8.95× | ||
| Q3 24 | 0.70× | 9.93× | ||
| Q2 24 | 1.42× | 1.27× | ||
| Q1 24 | -0.12× | -0.84× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
DFIN
| Technology Service | $68.0M | 39% |
| Capital Markets Compliance And Communications Management | $61.6M | 36% |
| Investment Companies Software Solutions | $30.9M | 18% |
| Print And Distribution Service | $13.6M | 8% |
